Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis: Results of an open-label post-certification study

Kidney and Blood Pressure Research

Volumn 27, Issue 4, 2004, Pages 211-217

  Klingel, Reinhard ^a,b,e   Schwarting, Andreas ^b   Lotz, Johannes ^b   Eckert, Martin ^c   Hohmann, Volker ^d   Hafner, Gerd ^b  

^a Apheresis Research Institute   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Institute for Statistics (SIMW)   (Germany)

^d SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^e Apheresis Research Institute   (Germany)

Author keywords

Anticoagulation; Enoxaparin; Hemodialysis; Low molecular weight heparin; Single bolus anticoagulation

Indexed keywords

ENOXAPARIN;

ADULT; AGED; ANTICOAGULATION; ARTERY BLOOD FLOW; ARTICLE; BLOOD CLOTTING DISORDER; BOLUS INJECTION; CAUSE OF DEATH; CLINICAL EXAMINATION; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MUSCLE NECROSIS; PRIORITY JOURNAL; RETINA HEMORRHAGE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; MIDDLE AGED; RENAL DIALYSIS; THROMBOSIS;

EID: 4644335491     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079866     Document Type: Article

References (22)

1. Lai KN, Ho K, Cheung RCK, Lit LCW, Lee SKM, Fung KS, Tong MKL, Lam CWK: Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis. Int J Artif Organs 2001;24:447-455.
2. Leitienne P, Fouque D, Rigal D, Adeleine P, Trceziak MC, Laville M: Heparins and blood polymorphonuclear stimulation in haemodialysis: An expansion of the biocompatibility concept. Nephrol Dial Transplant 2000;15:1631-1637.
3. Manduteanu I, Voinea M, Capraru M, Dragomir E, Simionescu M: A novel attribute of enoxaparin: Inhibition of monocyte adhesion to endothelial cells by a mechanism involving cell adhesion molecules. Pharmacology 2002;65:32-37.
4. Naumnik B, Borawski J, Mysliwiec M: Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: A prospective study. Nephrol Dial Transplant 2003;18:1376-1382.
5. Ljungberg B, Jacobson SH, Lins LE, Pejler G: Effective anticoagulation by a low molecular weight heparin (Fragmin®) in hemodialysis with a highly permeable polysulfone membrane. Clin Nephrol 1992;38:97-100.
6. Sagedal S, Hartmann A, Sundstrom K, Bjornsen S, Fauchald P, Brosstad F: A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrol Dial Transplant 1999;14:1943-1947.
7. Weitz JI: Low-molecular-weight heparins. N Engl J Med 1997;337:688-698.
8. Lane DA, Bowry SK: The scientific basis for selection of measures of thrombogenicity. Nephrol Dial Transplant 1994;9(suppl 2):18-28.
9. Hafner G, Klingel R, Wandel E, Ehrenthal U, Konheise U, Lotz H, Köhler H, Prellwitz W: Laboratory control of minimal heparinization during hemodialysis in patients with a risk of hemorrhage. Blood Coagul Fibrinolysis 1994;5:221-226.
10. Klingel R, Schaefer M, Schwarting A, Himmelsbach F, Altes U, Uhlenbusch-Körwer I, Hafner G: Comparative analysis of procoagulatory activity of hemodialysis, hemofiltration, and hemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation. Nephrol Dial Transplant 2004;19:164-170.
11. Matthews JNS, Hoenich NA: Statistical aspects of the design and analysis of studies to compare haemodialysis membranes. Nephrol Dial Transplant 1994;9(suppl 2):176-183.
12. Stefoni S, Cianciolo G, Donati G, Coli L, La Manna G, Raimondi C, Dalmastri V, Orlandi V, D'Addio F: Standard heparin versus lowmolecular-weight heparin. A medium-term comparison in haemodialysis. Nephron 2002;92:589-600.
13. Saltissi D, Morgan C, Westhuyzen J, Haely H: Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant 1999;14:2698-2703.
14. Klingel R, Hafner G, Remke S, Türk K, Wandel E: Procoagulatory activity of low- and highflux dialyzer performance during hemodialysis under conditions of low-dose anticoagulation with low molecular weight heparin (abstract). Kidney Blood Press Res 1998;21:202.
15. Klingel R, Altes U, Remke S, Wandel E, Hafner G: Activation of coagulation during hemodialysis using single bolus anticoagulation or a combined bolus-continuous mode with low molecular weight heparin (abstract). Kidney Blood Press Res 1999;22:234.
16. Vlassopoulos D, Noussias C, Hadjipetrou A, Arvanitis D, Logothetis E, Magana P, Katopodis K, Hadjiconstantinou V: Long-term effect of low molecular weight heparin on serum lipids in hypertriglyceridemic chronic hemodialysis patients. J Nephrol 1997;10:111-114.
17. Wiemer J, Winkler K, Baustark M, Marz W, Scherberich JE: Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses. Nephrol Dial Transplant 2002;17:2231-2238.
18. Kronenberg F, König P, Lhotta K, Steinmetz A, Dieplinger H: Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients. Clin Nephrol 1995;43:399-404.
19. Greiber S, Weber U, Galle J, Brämer P, Schollmeyer P: Activated clotting time is not a sensitive parameter to monitor anticoagulation with low molecular weight heparin in hemodialysis. Nephron 1997;76:15-19.
20. Marmur JD, Anand SX, Bagga RS, Fareed J, Pan CM, Sharma SK, Richard MF: The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003;41:394-402.
21. Leu JG, Chiang SS, Lin SM, Pai JK, Jiang WW: Low molecular weight heparin in hemodialysis patients with bleeding tendency. Nephron 2000;86:499-501.
22. Bijsterfeld NR, Moons AH, Meijers JC, Tijssen JG, Buller HR, Levi M, Peters RJ: Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecularweight heparin. J Am Coll Cardiol 2002;39:811-817.